Polaris Venture Management Co. V L.L.C. acquired a new position in X4 Pharmaceuticals Inc (NASDAQ:XFOR) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 311,492 shares of the company’s stock, valued at approximately $5,423,000. X4 Pharmaceuticals accounts for 4.6% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its 6th largest holding. Polaris Venture Management Co. V L.L.C. owned approximately 2.51% of X4 Pharmaceuticals at the end of the most recent quarter.
Several research analysts have recently commented on the company. Cowen assumed coverage on X4 Pharmaceuticals in a research report on Wednesday, June 5th. They set an “outperform” rating for the company. Stifel Nicolaus assumed coverage on X4 Pharmaceuticals in a research report on Friday, June 7th. They set a “buy” rating and a $27.00 price target for the company. Finally, Canaccord Genuity assumed coverage on X4 Pharmaceuticals in a research report on Tuesday, May 21st. They set a “buy” rating and a $27.00 price target for the company.
XFOR opened at $15.66 on Friday. X4 Pharmaceuticals Inc has a 52 week low of $6.90 and a 52 week high of $44.34. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.59 and a current ratio of 1.59.
X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($6.67) EPS for the quarter. As a group, sell-side analysts forecast that X4 Pharmaceuticals Inc will post -4.08 EPS for the current year.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Featured Article: Retained Earnings
Want to see what other hedge funds are holding XFOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for X4 Pharmaceuticals Inc (NASDAQ:XFOR).
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.